TOVX - Theriva Biologics, Inc.

0.381
0.008   2.073%

Share volume: 11,283,784
Last Updated: 04-23-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.16%

PREVIOUS CLOSE
CHG
CHG%
$0.37
0.01
0.02%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
42%
Profitability 35%
Dept financing 33%
Liquidity 49%
Performance 50%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-7.07%
1 Month
79.80%
3 Months
89.74%
6 Months
10.43%
1 Year
-73.04%
2 Year
3.36%
Key data
Stock price
$0.38
P/E Ratio 
N/A
DAY RANGE
$0.35 - $0.40
EPS 
-$4.22
52 WEEK RANGE
$0.16 - $1.46
52 WEEK CHANGE
-$73.19
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
45.893 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
04-29-2025
BETA 
1.15
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$107,297,254
AVERAGE 30 VOLUME 
$44,277,653
Company detail
CEO: Steven A. Shallcross
Region: US
Website: therivabio.com
Employees: 20
IPO year: 2012
Issue type: Common Stock
Market: NYSE American
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Synthetic Biologics, Inc. develops therapeutics to treat diseases in areas of high unmet need. The company's lead product candidates include SYN-004 designed to degrade intravenous beta-lactam antibiotics in gastrointestinal (GI) tract. It also develops VCN-01 for the treatment of patients with pancreatic cancer, head and neck squamous cell carcinoma, colorectal cancer, and retinoblastoma.

Recent news